Business Description
Mereo BioPharma Group PLC
SIC : 2836
ISIN : US5894921072
Share Class Description:
MREO: ADRTotal Employee Number:
39Description
Mereo BioPharma Group PLC is a clinical-stage biopharmaceutical company based in the United Kingdom that develops therapeutics for rare diseases. Its lead rare disease candidate is setrusumab, an anti-sclerostin antibody being developed for osteogenesis imperfecta in partnership with Ultragenyx Pharmaceutical, which leads global development and commercialization. The company also develops alvelestat, an oral neutrophil elastase inhibitor, for alpha-1 antitrypsin deficiency-associated lung disease and other neutrophil-driven conditions. Mereo's pipeline additionally includes earlier-stage and partnerable assets in oncology and endocrine disease. As a clinical-stage company, Mereo does not market approved products and generates no significant product revenue; it funds operations through equity financings, licensing and collaboration agreements, and partnership milestones. Its activities are centered in the United Kingdom, with clinical trials and partnering efforts conducted internationally.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 29.24 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.8 | |||||
3-Year EPS without NRI Growth Rate | 21.7 | |||||
3-Year FCF Growth Rate | 21.5 | |||||
3-Year Book Growth Rate | -14.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.29 | |||||
9-Day RSI | 64.29 | |||||
14-Day RSI | 58.48 | |||||
3-1 Month Momentum % | 1.16 | |||||
6-1 Month Momentum % | -11 | |||||
12-1 Month Momentum % | -82.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.88 | |||||
Quick Ratio | 5.88 | |||||
Cash Ratio | 5.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.4 | |||||
Shareholder Yield % | 6.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -5044 | |||||
OCF Margin % | -5044.03 | |||||
ROE % | -68.74 | |||||
ROA % | -59.16 | |||||
ROIC % | -1152.52 | |||||
3-Year ROIIC % | -76.74 | |||||
ROC (Joel Greenblatt) % | -4781.84 | |||||
ROCE % | -67.42 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 96.13 | |||||
PB Ratio | 1.61 | |||||
Price-to-Tangible-Book | 1.61 | |||||
EV-to-EBIT | -0.54 | |||||
EV-to-EBITDA | -0.56 | |||||
EV-to-Revenue | 31.33 | |||||
EV-to-FCF | -0.62 | |||||
| Price-to-Net-Current-Asset-Value | 1.71 | |||||
| Price-to-Net-Cash | 1.93 | |||||
Earnings Yield (Greenblatt) % | -185.19 | |||||
FCF Yield % | -54.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MREO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mereo BioPharma Group PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.501 | ||
| EPS (TTM) ($) | -0.175 | ||
| Beta | 0.3102 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 92.18 | ||
| 14-Day RSI | 58.48 | ||
| 14-Day ATR ($) | 0.02412 | ||
| 20-Day SMA ($) | 0.27245 | ||
| 12-1 Month Momentum % | -82.32 | ||
| 52-Week Range ($) | 0.2 - 2.37 | ||
| Shares Outstanding (Mil) | 159.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mereo BioPharma Group PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mereo BioPharma Group PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-19 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-19 | In 178 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 49 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 0.27 (-8.90%) | ||
| General meeting for 2026 | 2026-05-14 09:00 | 0.26 (+3.59%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.24 (-2.88%) | ||
| Annual report for 2025 | 2026-03-19 | 0.35 (-5.46%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 0.35 (-5.46%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 1.80 (+3.45%) | ||
| Cantor Global Healthcare Conference | 2025-09-04 08:35 | 1.73 (-3.35%) |
Show
Entries
Mereo BioPharma Group PLC Frequently Asked Questions
What is Mereo BioPharma Group PLC(MREO)'s stock price today?
The current price of MREO is $0.29. The 52 week high of MREO is $2.37 and 52 week low is $0.20.
When is next earnings date of Mereo BioPharma Group PLC(MREO)?
The next earnings date of Mereo BioPharma Group PLC(MREO) is 2026-11-10 Est..
Does Mereo BioPharma Group PLC(MREO) pay dividends? If so, how much?
Mereo BioPharma Group PLC(MREO) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers